Table 1.

Overview of experimental groups, sample sizes, and variables

ExperimentTotal miceSurvival timeVirus treatment and titerImaging
CTB colabel (uninjured)133, 7, or 14 dRetro-AAV-tdTomato (3.8 × 1012 GC/ml)2D
Retro-AAV-EGFP (3.9 × 1012 GC/ml)
CTB colabel (injured)828 dRetro-AAV-tdTomato (3.8 × 1012 GC/ml)2D
Cervical retrograde (3D)42 weeksRetro-AAV-tdTomato (3.8 × 1012 GC/ml)3D
Dual label (cervical/lumbar) (3D)44 weeksRetro-AAV-tdTomato (3.8 × 1012 GC/ml)3D
Retro-AAV-EGFP (3.9 × 1012 GC/ml)
DREADD behavior, wild-type12Behavior weeks 2–4; killed at 4 weeksRetro-AAV-CRE (8.1 × 1012 GC/ml)2D
Retro-AAV-Flex-Gi-DREADD (9.0 × 1012 GC/ml)
DREADD behavior, CaMKIIa-Cre6Behavior weeks 2–4; killed at 4 weeksRetro-AAV-Flex-Gi-DREADD (9.0 × 1012 GC/ml)2D
  • Statistical comparisons of transduction efficiencies between all suprapsinal populations are provided in Table 1-2.